-
1 Comment
Tekla Life Sciences Investors is currently in a long term uptrend where the price is trading 6.7% above its 200 day moving average.
From a valuation standpoint, the stock is 57.0% cheaper than other stocks from the Financial Services sector with a price to sales ratio of 3.9.
Tekla Life Sciences Investors's total revenue rose by 65.9% to $2M since the same quarter in the previous year.
Its net income has increased by 196.2% to $30M since the same quarter in the previous year.
Based on the above factors, Tekla Life Sciences Investors gets an overall score of 4/5.
None
Here's how to backtest a trading strategy or backtest a portfolio for HQL using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
